Dramatic Cures for Children with No Prospects Using Standard Therapies for T-cell malignancies
https://www.audiomedica.com/wp-content/2025/12/251209-0900-Peihua-Lu-Robert-Chiesa-C2998-Discussion-at-ASH-AJO-PRODUCTION-MASTER.mp3Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies
A discussion interview with Peihua Lu MD from Lu Daopei Hospital in Beijing, China and Robert Chiesa MD PhD from Great Ormond Street Hospital for Children, London, UK, at the American Society of Hematology Annual Meeting in Orlando, Florida, USA
ORLANDO, USA—Children and young adults whose T-cell malignancies had become refractory to all standard treatments have been rescued by means of two different chimeric antigen receptor T-cell therapies: one developed commercially in China and the other created in the laboratory of a leading children’s hospital in London by means of a new method of engineering DNA called: “base editing”.
At the 2025 American Society of Hematology annual meeting in Orlando, Florida, lead author of the Chinese study, Peihua Lu MD from Lu Daopei Hospital in Beijing and team-leader Robert Chiesa MD PhD from Great Ormond Street Hospital for Children, London, UK, met up with Audio Journal of Oncology anchor, Peter Goodwin, to discuss their pioneering early studies which seem to offer hope for patients and their families.
Audio Journal of Oncology: Peihua Lu MD and Robert Chiesa MD PhD
IN: “[GOODWIN] Welcome to…. OUT: ……..from all of us, Good-bye ” 33:51
A discussion on ASH ABSTRACTS at the 2025 Annual Meeting:
Abstract 1042: “CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) – report of clinical outcomes at the recommended phase 2 dose (RP2D)”
Abstract 1041: “Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia”
Tags
Related Episodes
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca
Amy A. Kirkwood MSc: Options Identified for Chemotherapy Intensity Reduction in Acute Lymphoblastic Leukemia
Amy A. Kirkwood MSc
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.